Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.
You may also be interested in...
Shire's Fosrenol Is Boosting ESRD Market, Not Switching Renagel Patients, Genzyme Says
Renagel remains healthy despite competition from Shire's phosphate-control agent, the company maintains. Genzyme continues to see opportunities for its end-stage renal disease therapy with Medicare Part D.
Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch
Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.